Vancomycin protein binding in patients with infections caused by Staphylococcus aureus
- PMID: 1949924
- DOI: 10.1177/106002809102500701
Vancomycin protein binding in patients with infections caused by Staphylococcus aureus
Abstract
The protein binding of vancomycin has been reported to range from less than 10 percent to 82 percent. We examined the binding of vancomycin in 34 patients (14 intravenous drug abusers, 10 burn patients, and 10 control patients) with Staphylococcus aureus infections. Blood samples were collected serially over an 8- or 12-hour dosing interval following a one-hour infusion. In vitro studies were also performed using albumin solutions of varying concentrations. Binding characteristics were determined through ultrafiltration with vancomycin concentrations analyzed for fluorescence polarization immunoassay. The unbound fraction of vancomycin ranged from 0.41 to 0.77 with a mean of 0.54 +/- 0.08. Unbound fractions was significantly correlated with serum albumin concentration (r = -0.344, p less than 0.046) and renal clearance (r = 0.394, p less than 0.021) but not with total body clearance or volume of distribution. In vitro data also showed an association between albumin concentration and unbound fraction (r = -0.94, p less than 0.017). Although vancomycin protein binding changes with serum albumin, this finding may have limited clinical significance.
Similar articles
-
Vancomycin serum protein binding determination by ultrafiltration.Drug Intell Clin Pharm. 1988 Apr;22(4):300-3. doi: 10.1177/106002808802200404. Drug Intell Clin Pharm. 1988. PMID: 3371190
-
Supratherapeutic Vancomycin Concentrations Associated With Hypothermia in a Burn Patient.J Burn Care Res. 2018 Oct 23;39(6):1058-1063. doi: 10.1093/jbcr/irx038. J Burn Care Res. 2018. PMID: 29931313
-
Pharmacokinetics of vancomycin in extremely obese patients with suspected or confirmed Staphylococcus aureus infections.Pharmacotherapy. 2015 Feb;35(2):127-39. doi: 10.1002/phar.1531. Epub 2015 Feb 3. Pharmacotherapy. 2015. PMID: 25644478
-
The importance of tissue penetration in achieving successful antimicrobial treatment of nosocomial pneumonia and complicated skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus: vancomycin and linezolid.Curr Med Res Opin. 2010 Mar;26(3):571-88. doi: 10.1185/03007990903512057. Curr Med Res Opin. 2010. PMID: 20055750 Review.
-
Ceftobiprole: a review of a broad-spectrum and anti-MRSA cephalosporin.Am J Clin Dermatol. 2008;9(4):245-54. doi: 10.2165/00128071-200809040-00004. Am J Clin Dermatol. 2008. PMID: 18572975 Review.
Cited by
-
Analytical Validation of Aptamer-Based Serum Vancomycin Monitoring Relative to Automated Immunoassays.ACS Sens. 2024 Jan 26;9(1):228-235. doi: 10.1021/acssensors.3c01868. Epub 2023 Dec 18. ACS Sens. 2024. PMID: 38110361 Free PMC article.
-
Pharmacokinetics and pharmacodynamics of peptide antibiotics.Adv Drug Deliv Rev. 2022 Apr;183:114171. doi: 10.1016/j.addr.2022.114171. Epub 2022 Feb 18. Adv Drug Deliv Rev. 2022. PMID: 35189264 Free PMC article. Review.
-
Comparative efficacies of human simulated exposures of telavancin and vancomycin against methicillin-resistant Staphylococcus aureus with a range of vancomycin MICs in a murine pneumonia model.Antimicrob Agents Chemother. 2010 Dec;54(12):5115-9. doi: 10.1128/AAC.00062-10. Epub 2010 Sep 13. Antimicrob Agents Chemother. 2010. PMID: 20837760 Free PMC article.
-
Analysis of vancomycin entry into pulmonary lining fluid by bronchoalveolar lavage in critically ill patients.Antimicrob Agents Chemother. 1993 Feb;37(2):281-6. doi: 10.1128/AAC.37.2.281. Antimicrob Agents Chemother. 1993. PMID: 8452359 Free PMC article.
-
Population pharmacokinetics of arbekacin, vancomycin, and panipenem in neonates.Antimicrob Agents Chemother. 2004 Apr;48(4):1159-67. doi: 10.1128/AAC.48.4.1159-1167.2004. Antimicrob Agents Chemother. 2004. PMID: 15047516 Free PMC article. Clinical Trial.
MeSH terms
Substances
LinkOut - more resources
Medical